MetLife Investment Advisors LLC bought a new position in shares of Ignyta Inc (NASDAQ:RXDX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 24,664 shares of the biopharmaceutical company’s stock, valued at approximately $659,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in RXDX. Eagle Asset Management Inc. bought a new position in shares of Ignyta during the fourth quarter worth approximately $60,248,000. Gardner Lewis Asset Management L P bought a new position in shares of Ignyta during the fourth quarter worth approximately $49,431,000. Alliancebernstein L.P. increased its stake in shares of Ignyta by 1,414.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,746,002 shares of the biopharmaceutical company’s stock worth $46,618,000 after purchasing an additional 1,630,702 shares during the period. Carillon Tower Advisers Inc. bought a new position in shares of Ignyta during the fourth quarter worth approximately $41,780,000. Finally, Alpine Associates Management Inc. bought a new position in shares of Ignyta during the fourth quarter worth approximately $41,028,000. Institutional investors own 72.28% of the company’s stock.
Ignyta stock opened at $26.98 on Tuesday. Ignyta Inc has a one year low of $5.80 and a one year high of $27.10. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.34.
TRADEMARK VIOLATION NOTICE: “MetLife Investment Advisors LLC Takes $659,000 Position in Ignyta Inc (RXDX)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2018/04/17/metlife-investment-advisors-llc-takes-659000-position-in-ignyta-inc-rxdx.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.